Legend Biotech (LEGN) Share-based Compensation (2020 - 2026)
Legend Biotech's (LEGN) quarterly Share-based Compensation came in at $19.3 million in Q1 2026, up 21.38% YoY from $15.9 million in Q1 2025, and up 28.54% on a QoQ basis from $15.0 million in Q3 2025.
Legend Biotech (LEGN) Share-based Compensation (2020 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Share-based Compensation data on file, last reported at $19.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 21.38% year-over-year to $19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.0 million (up 4.26% YoY) and the FY2024 annual result came in at $68.9 million, up 44.59% from the prior year.
- Share-based Compensation rose to $19.3 million in Q1 2026, from $15.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $21.7 million in Q2 2024 to a low of $5.7 million in Q1 2022.
- A 5-year average of $13.7 million and a median of $14.2 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation jumped 164.58% — and 2025, when it decreased 14.99%.
- Tracing LEGN's Share-based Compensation over 5 years: stood at $9.0 million in 2022, then soared by 40.3% to $12.6 million in 2023, then grew by 6.35% to $13.4 million in 2024, then advanced by 12.15% to $15.0 million in 2025, then climbed by 28.54% to $19.3 million in 2026.
- The last three Share-based Compensation figures came in at $19.3 million (Q1 2026), $15.0 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 17.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.40 Mn |
| Jun 30, 2026 | 17.40 Mn |
| Mar 31, 2026 | 19.30 Mn |
| Mar 31, 2026 | 19.30 Mn |
| Sep 30, 2025 | 15.02 Mn |
| Sep 30, 2025 | 15.02 Mn |
| Jun 30, 2025 | 18.74 Mn |
| Jun 30, 2025 | 18.74 Mn |
| Mar 31, 2025 | 15.90 Mn |
| Mar 31, 2025 | 15.90 Mn |
| Dec 31, 2024 | 13.39 Mn |
| Dec 31, 2024 | 13.39 Mn |
| Sep 30, 2024 | 15.11 Mn |
| Sep 30, 2024 | 15.11 Mn |
| Jun 30, 2024 | 21.74 Mn |
| Jun 30, 2024 | 21.74 Mn |
| Mar 31, 2024 | 18.70 Mn |
| Mar 31, 2024 | 18.70 Mn |
| Dec 31, 2023 | 12.59 Mn |
| Dec 31, 2023 | 12.59 Mn |